EFGCP Steps Up Search for COO
Applications for the vacant Brussels-based post of chief operating officer at the European Forum for GCP (EFGCP) are due to close on Friday August 18. EFGCP says it has earmarked a proposed start date of September 18 for the successful candidate.
The role will involve the following responsibilities:
- ÂManagement of events, including conferences and workshops for between 40 and 150 participants and training courses.
- ÂFinding venues for events, negotiating contracts, handling logistics, managing speakers and delegates, and overseeing marketing and promotions.
- ÂProject management, including administrative and financial management of EFGCP participation in EU-funded projects and preparation of financial audits.
- ÂCoordination of internal meetings, managing the website and IT, public representation, office management, and accounting, VAT, and legal issues.
- ÂHuman resources (management of payroll and three-person staff).
According to the EFGCP, “The applicant should have strong self-motivation, interpersonal skills, be multi-tasks-oriented, possibly have experience in the healthcare sector and be able to work in a small team environment.”
It lists the job requirements as: experience in a coordination position and event organization; excellent written and oral communication skills in English (French is an asset); knowledge of financial management and bookkeeping and legal rules for associations based in Belgium; very well organized and caring for details; flexible, positive, and service-minded; excellent time management and respect of deadlines; and creative and resourceful problem-solving abilities.
Applications should include a CV in English and a one-page covering letter in English and be sent to jobs@efgcp.eu
Philip Ward is the European Editor for Applied Clinical Trials.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
